SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
--------------
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. )*
INTERLEUKIN GENETICS, INC.
-----------------------------------------------------------------------
(Name of issuer)
COMMON STOCK, NO PAR VALUE PER SHARE
-----------------------------------------------------------------------
(Title of class of securities)
458738101
-----------------------------------------------------------------------
(CUSIP number)
Cathy M. Fine
-----------------------------------------------------------------------
(Name, address and telephone number of person
authorized to receive notices and communications)
April 6, 2001**
-----------------------------------------------------------------------
(Date of event which requires filing of this statement)
If the filing person has previously filed a statement on Schedule 13Gto
report the acquisition which is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(b)(3) or (4), check the following box / /.
NOTE. Six copies of this statement, including all exhibits, should be filed
with the Commission. SEE Rule 13d-1(a) for other parties to whom copies are to
be sent.
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
** This filing is a voluntary disclosure.
------------------------ --------------------
CUSIP No. 458738101 Page 1 of 5 Pages
================================================================================
1 NAME OF REPORTING PERSON'S S.S. OR I.R.S. IDENTIFICATION NO.
(entities only)
048-54-8448
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) / /
(b) /X/
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
PF
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) / /
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Connecticut
--------------------------------------------------------------------------------
NUMBER OF SHARES 7 SOLE VOTING POWER
BENEFICIALLY 1,641,000
OWNED BY ---------------------------------------------------------
EACH 8 SHARED VOTING POWER
REPORTING -0-
PERSON WITH ---------------------------------------------------------
9 SOLE DISPOSITIVE POWER
1,641,000
---------------------------------------------------------
10 SHARED DISPOSITIVE POWER
-0-
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
1,641,000
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)
EXCLUDES CERTAIN SHARES* / /
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
7.7%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IN
================================================================================
*SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP No. 458738101 13D Page 2 of 5 Pages
Item 1. Security And Issuer.
--------------------
This statement relates to the shares ("Shares") of common stock, no par
value ("Common Stock"), of Interleukin Genetics, Inc. ("Issuer"). The principal
executive offices of the Issuer are located at 135 Beaver Street, Waltham,
Massachusetts.
Item 2. Identity and Background.
------------------------
(a) Name: Cathy Fine(the "Reporting Person").
(b) The principal business address of the Reporting Person is 131 Talmadge
Hill Road, New Canaan, CT 06840.
(c) The present principal business of the Reporting Person is private
investor.
(d) The Reporting Person has not, during the last five years, been
convicted in a criminal proceeding (excluding traffic violations or similar
misdemeanors).
(e) The Reporting Person has not, during the last five years, been party to
a civil proceeding of a judicial or administrative body of competent
jurisdiction and as a result of such proceeding was or is subject to a judgment,
decree or final order enjoining future violations of, or prohibiting or
mandating activities subject to, federal or state securities laws or finding any
violation with respect to such laws.
(f) The Reporting Person is a citizen of Connecticut.
CUSIP No. 458738101 13D Page 3 of 5 Pages
Item 3. Source And Amount Of Funds Or Other Consideration.
--------------------------------------------------
Mrs. Fine used her personal funds for this purchase.
Item 4. Purpose Of Transaction.
-----------------------
The purpose of the acquisition of these shares is for investment purposes.
The Reporting Person may acquire additional shares or dispose of shares from
time to time. Also, the Reporting Person reserves the right to change investment
intentions based upon circumstances. Currently, the Reporting Person has no plan
or proposal which relates to the following (although she reserves the right to
develop such plans or proposals): (i) the acquisition of additional securities
of the Issuer, or the disposition of securities of the Issuer: (ii) an
extraordinary corporate transaction, such as a merger, reorganization or
liquidation, involving the Issuer or any of its subsidiaries; (iii) a sale or
transfer of a material amount of assets of the Issuer or any of its
subsidiaries; (iv) a change in the present board of directors or management of
the Issuer, including any plans or proposals to change the number or term of
directors or to fill any existing vacancies on the Issuer's board of
directors;(v) a material change in the present capitalization or dividend policy
of the Issuer; (vi) any other material change in the business or corporate
structure of the Issuer; (vii) any change in the Issuer's certificate of
incorporation or by-laws or other actions which may impede the acquisition of
control of the Issuer by any person; (viii) causing a class of securities of the
Issuer to be delisted from a national securities exchange or to cease to be
authorized to be quoted in an inter-dealer quotation system of a registered
national securities association; (ix) a class of equity securities of the Issuer
becoming eligible for termination of registration pursuant to Section 12(g)(4)
of the Exchange Act; or (x) any action similar to any of those enumerated above.
Item 5. Interest In Securities Of The Issuer.
-------------------------------------
Cathy M. Fine is the beneficial owner of 1,641,000 shares of the Issuer's
Common Stock (representing 7.7% of the issued and outstanding Common Stock). Of
these 1,641,000 shares, Mrs. Fine has sole voting and dispositive power over
1,641,000 shares.
CUSIP No. 458738101 13D Page 4 of 5 Pages
During the last 60 days the following shares were acquired by the Reporting
Person:
Between February 1, 2001 and February 14, 2001, Mrs. Fine acquired 35,000
shares of the Issuer's common stock through open market purchases at an average
price of $3.25 per share.
On April 6, 2001, Mrs. Fine exercised her warrant to acquire 803,000 shares
of the Issuer's common stock.
Item 6. Contracts, Arrangements, Understandings or Relationships With
Respect To Securities Of The Issuer.
---------------------------------------------------------------------
There is no contract between the Reporting Persons or any other person with
respect to any securities of the Issuer including, but not limited to transfer
or voting of any security, finder's fees, joint ventures, loan or options
arrangements, puts or calls, guarantees of profits, division of profit or
losses, or the giving or holding of proxies, except as described herein.
SIGNATURE
---------
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: April 18, 2001
By: /s/ Cathy M. Fine
------------------------------
Cathy M. Fine
--------------------------------------------------------------------------------
CUSIP No. 458738101 13D Page 5 of 5 Pages